Biobank for patients with cardiac arrhythmias

"Arrhythmia and Conduction Disorders: TowArd Pathophysiology Based Treatment" ADAPT Biobank

This study is collecting samples and information from patients with heart rhythm problems to better understand their condition and find more personalized treatment options.

Quick facts

• Study type: Observational
• Enrollment: 1000 (estimated)
• Ages: 18 Years and up
• Sex: All
• Sponsor: Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) (other)
• Locations: 1 site (Amsterdam)
• Trial ID: NCT04776642 on ClinicalTrials.gov

What this trial studies

The ADAPT Biobank collects biological materials and data from patients with or at risk of cardiac arrhythmias who are undergoing various treatments. Its primary goal is to enhance understanding of the complex pathophysiology of arrhythmias by gathering comprehensive patient information and samples. This biobank will facilitate biochemical, histological, and molecular analyses to identify patient subgroups that may benefit from tailored treatment strategies. The collected data will be linked to participants' medical records for longitudinal follow-up and future research opportunities.

Who should consider this trial

Good fit: Ideal candidates include patients visiting the AMC outpatient clinic who have cardiac arrhythmias or are involved in related clinical trials.

Not a fit: Patients without cardiac arrhythmias or those not participating in linked clinical trials may not benefit from this biobank.

Why it matters

Potential benefit: If successful, this biobank could lead to more personalized treatment options and improved prognostic capabilities for patients with cardiac arrhythmias.

How similar studies have performed: Other biobanks focusing on cardiovascular diseases have shown promise in advancing research, indicating that this approach could be beneficial.

Eligibility criteria

Inclusion criteria:

* Patients visiting the AMC outpatient clinic
* Patients included in an ongoing clinical trial linked to this biobank. Studies are listed under point "Groups and interventions" and include:

  * MARK AF
  * INDICO AF
  * PREDICT AF
  * WEIGHTLOSS AF
  * MAD AF
* Patients included in future clinical trial linked to this biobank. Studies may be linked to this biobank that investigates prevalent or incident cardiac arrhythmias.
* Cardiac arrhtymias are defined as

  * Supraventricular tachycardia, among which the most common are:

    * Atrial Fibrillation (AF)
    * Atrial Tachycardia (AT)
    * Atrial Flutter (AFL)
    * Atrioventricular Nodal Reentrant Tachycardia (AVNRT)
    * Atrioventricular Reentrant Tachycardia (AVRT)
  * Ventricular tachycardia, among which the most common are:

    * Ventricular Tachycardia (VT)
    * Ventricular Flutter (VFL)
    * Ventricular Fibrillation (VF)
  * Bradycardia:

    * Sinus Node Dysfunction
    * AV Node Dysfunction
    * Interventricular Conduction Disorder
  * Arrhythmogenic cardiomyopathies, among which the most common are:

    * Dilated Cardiomyopathy
    * Restrictive Cardiomyopathy
    * Arrhythmogenic Right Ventricular Cardiomyopathy (ARVC)

Exclusion criteria (shared for all studies):

* Age \< 18
* Unable or unwilling to comply with study procedures
* Pregnancy or of childbearing potential without adequate contraception
* NYHA class IV heart failure symptoms or left ventricular ejection fraction \<35%.

Where this trial is running

Amsterdam

• Amsterdam University Medical Center location AMC — Amsterdam, Netherlands (RECRUITING)

Study contacts

• Principal investigator: Joris de Groot, MD, PhD — Amsterdam UMC - AMC
• Study coordinator: Elise Hulsman, Bc RN

Conditions: Arrythmia, Conduction Disorder, Pathophysiology